Cargando…
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
Assessing the phenotypic diversity underlying tumour progression requires the identification of variations in the respective molecular interaction networks. Here we report proof-of-concept for a platform called poly-ligand profiling (PLP) that surveys these system states and distinguishes breast can...
Autores principales: | Domenyuk, Valeriy, Gatalica, Zoran, Santhanam, Radhika, Wei, Xixi, Stark, Adam, Kennedy, Patrick, Toussaint, Brandon, Levenberg, Symon, Wang, Jie, Xiao, Nianqing, Greil, Richard, Rinnerthaler, Gabriel, Gampenrieder, Simon P., Heimberger, Amy B., Berry, Donald A., Barker, Anna, Quackenbush, John, Marshall, John L., Poste, George, Vacirca, Jeffrey L., Vidal, Gregory A., Schwartzberg, Lee S., Halbert, David D., Voss, Andreas, Magee, Daniel, Miglarese, Mark R., Famulok, Michael, Mayer, Günter, Spetzler, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865185/ https://www.ncbi.nlm.nih.gov/pubmed/29572535 http://dx.doi.org/10.1038/s41467-018-03631-z |
Ejemplares similares
-
Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach
por: Domenyuk, Valeriy, et al.
Publicado: (2017) -
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
por: Vanderwalde, Ari, et al.
Publicado: (2018) -
Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
por: Gampenrieder, Simon P., et al.
Publicado: (2013) -
CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016) -
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)